They would not pay CYTO $2MM for an option without being pretty confident of CMS scheduling. CMS scheduling could mean $200MM of sales pretty fast especially with a this already established sales force (probably Abbot Labs). Chronic wounds are the most critical need in extended care and hospice. They will try anything new as long as Medicare pays for it. The best part is this product actually works to heal and relieve suffering. With approval, the stock should gap up to $3. Pretty good risk/reward. After a couple of years it will $10 and then sell to Abbot.
How often do we get to invest this early in a company with an FDA approved product at a $40MM valuation. This is as good as it gets. Cannot believe the stock is not $2 or $100MM valuation. The stock was $.60 in January and it has made quantum progress since then.
A lot of folks have made good money here in a short time. Lots of reasons not to trust the markets or the gov regulators. So selling into strength has been strong and maybe wise. And that is a good thing, as it gives us more of a base, and room to rise as more good news comes. I agree that any more postitive development, and this works up to a dollar without even being frothy. Will they try to re-list?